<!DOCTYPE html>
<html lang="en-US">
  <!-- Mirrored from bridgebio.com/news/bridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update/ by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 18 Dec 2024 11:01:30 GMT -->
  <!-- Added by HTTrack --><meta
    http-equiv="content-type"
    content="text/html;charset=UTF-8"
  /><!-- /Added by HTTrack -->
  <head>
    <title>Third Quarter 2022 Financial Results | BridgeBio</title>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, maximum-scale=5.0, minimum-scale=1"
    />
    <meta
      name="robots"
      content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"
    />

    <!-- This site is optimized with the Yoast SEO plugin v23.4 - https://yoast.com/wordpress/plugins/seo/ -->
    <meta
      name="description"
      content="BridgeBio reported its financial results for the third quarter ended September 30, 2022 and provided an update on the Company’s operations. Learn more."
    />
    <link rel="canonical" href="index.html" />
    <meta property="og:locale" content="en_US" />
    <meta property="og:type" content="article" />
    <meta
      property="og:title"
      content="Third Quarter 2022 Financial Results | BridgeBio"
    />
    <meta
      property="og:description"
      content="BridgeBio reported its financial results for the third quarter ended September 30, 2022 and provided an update on the Company’s operations. Learn more."
    />
    <meta property="og:url" content="index.html" />
    <meta property="og:site_name" content="BridgeBio" />
    <meta
      property="article:published_time"
      content="2022-11-03T11:30:27+00:00"
    />
    <meta
      property="article:modified_time"
      content="2023-02-17T13:54:06+00:00"
    />
    <meta
      property="og:image"
      content="../../wp-content/uploads/2019/02/BridgeBio_Share.png"
    />
    <meta property="og:image:width" content="1200" />
    <meta property="og:image:height" content="600" />
    <meta property="og:image:type" content="image/png" />
    <meta name="author" content="Holly Condon" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:creator" content="@BridgeBioPharma" />
    <meta name="twitter:site" content="@BridgeBioPharma" />
    <meta name="twitter:label1" content="Written by" />
    <meta name="twitter:data1" content="Holly Condon" />
    <meta name="twitter:label2" content="Est. reading time" />
    <meta name="twitter:data2" content="21 minutes" />
    <script type="application/ld+json" class="yoast-schema-graph">
      {
        "@context": "https://schema.org",
        "@graph": [
          {
            "@type": "WebPage",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update/",
            "url": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update/",
            "name": "Third Quarter 2022 Financial Results | BridgeBio",
            "isPartOf": { "@id": "https://bridgebio.com/#website" },
            "datePublished": "2022-11-03T11:30:27+00:00",
            "dateModified": "2023-02-17T13:54:06+00:00",
            "author": {
              "@id": "https://bridgebio.com/#/schema/person/e56e9128cd840531b0acdca992cb1fca"
            },
            "description": "BridgeBio reported its financial results for the third quarter ended September 30, 2022 and provided an update on the Company’s operations. Learn more.",
            "breadcrumb": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update/#breadcrumb"
            },
            "inLanguage": "en-US",
            "potentialAction": [
              {
                "@type": "ReadAction",
                "target": [
                  "https://bridgebio.com/news/bridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update/"
                ]
              }
            ]
          },
          {
            "@type": "BreadcrumbList",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update/#breadcrumb",
            "itemListElement": [
              {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "https://bridgebio.com/"
              },
              {
                "@type": "ListItem",
                "position": 2,
                "name": "BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update"
              }
            ]
          },
          {
            "@type": "WebSite",
            "@id": "https://bridgebio.com/#website",
            "url": "https://bridgebio.com/",
            "name": "BridgeBio",
            "description": "",
            "potentialAction": [
              {
                "@type": "SearchAction",
                "target": {
                  "@type": "EntryPoint",
                  "urlTemplate": "https://bridgebio.com/?s={search_term_string}"
                },
                "query-input": {
                  "@type": "PropertyValueSpecification",
                  "valueRequired": true,
                  "valueName": "search_term_string"
                }
              }
            ],
            "inLanguage": "en-US"
          },
          {
            "@type": "Person",
            "@id": "https://bridgebio.com/#/schema/person/e56e9128cd840531b0acdca992cb1fca",
            "name": "Holly Condon",
            "image": {
              "@type": "ImageObject",
              "inLanguage": "en-US",
              "@id": "https://bridgebio.com/#/schema/person/image/",
              "url": "https://secure.gravatar.com/avatar/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g",
              "contentUrl": "https://secure.gravatar.com/avatar/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g",
              "caption": "Holly Condon"
            },
            "url": "https://bridgebio.com/author/hcondon/"
          }
        ]
      }
    </script>
    <!-- / Yoast SEO plugin. -->

    <link rel="dns-prefetch" href="http://cdnjs.cloudflare.com/" />
    <link rel="dns-prefetch" href="http://unpkg.com/" />
    <link rel="dns-prefetch" href="http://fonts.googleapis.com/" />
    <link
      rel="alternate"
      type="application/rss+xml"
      title="BridgeBio &raquo; BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update Comments Feed"
      href="feed/index.html"
    />
    <script type="text/javascript">
      /* <![CDATA[ */
      window._wpemojiSettings = {
        baseUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/",
        ext: ".png",
        svgUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/",
        svgExt: ".svg",
        source: {
          concatemoji:
            "https:\/\/bridgebio.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.6.2",
        },
      };
      /*! This file is auto-generated */
      !(function (i, n) {
        var o, s, e;
        function c(e) {
          try {
            var t = { supportTests: e, timestamp: new Date().valueOf() };
            sessionStorage.setItem(o, JSON.stringify(t));
          } catch (e) {}
        }
        function p(e, t, n) {
          e.clearRect(0, 0, e.canvas.width, e.canvas.height),
            e.fillText(t, 0, 0);
          var t = new Uint32Array(
              e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
            ),
            r =
              (e.clearRect(0, 0, e.canvas.width, e.canvas.height),
              e.fillText(n, 0, 0),
              new Uint32Array(
                e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
              ));
          return t.every(function (e, t) {
            return e === r[t];
          });
        }
        function u(e, t, n) {
          switch (t) {
            case "flag":
              return n(
                e,
                "\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f",
                "\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f"
              )
                ? !1
                : !n(
                    e,
                    "\ud83c\uddfa\ud83c\uddf3",
                    "\ud83c\uddfa\u200b\ud83c\uddf3"
                  ) &&
                    !n(
                      e,
                      "\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f",
                      "\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f"
                    );
            case "emoji":
              return !n(
                e,
                "\ud83d\udc26\u200d\u2b1b",
                "\ud83d\udc26\u200b\u2b1b"
              );
          }
          return !1;
        }
        function f(e, t, n) {
          var r =
              "undefined" != typeof WorkerGlobalScope &&
              self instanceof WorkerGlobalScope
                ? new OffscreenCanvas(300, 150)
                : i.createElement("canvas"),
            a = r.getContext("2d", { willReadFrequently: !0 }),
            o = ((a.textBaseline = "top"), (a.font = "600 32px Arial"), {});
          return (
            e.forEach(function (e) {
              o[e] = t(a, e, n);
            }),
            o
          );
        }
        function t(e) {
          var t = i.createElement("script");
          (t.src = e), (t.defer = !0), i.head.appendChild(t);
        }
        "undefined" != typeof Promise &&
          ((o = "wpEmojiSettingsSupports"),
          (s = ["flag", "emoji"]),
          (n.supports = { everything: !0, everythingExceptFlag: !0 }),
          (e = new Promise(function (e) {
            i.addEventListener("DOMContentLoaded", e, { once: !0 });
          })),
          new Promise(function (t) {
            var n = (function () {
              try {
                var e = JSON.parse(sessionStorage.getItem(o));
                if (
                  "object" == typeof e &&
                  "number" == typeof e.timestamp &&
                  new Date().valueOf() < e.timestamp + 604800 &&
                  "object" == typeof e.supportTests
                )
                  return e.supportTests;
              } catch (e) {}
              return null;
            })();
            if (!n) {
              if (
                "undefined" != typeof Worker &&
                "undefined" != typeof OffscreenCanvas &&
                "undefined" != typeof URL &&
                URL.createObjectURL &&
                "undefined" != typeof Blob
              )
                try {
                  var e =
                      "postMessage(" +
                      f.toString() +
                      "(" +
                      [JSON.stringify(s), u.toString(), p.toString()].join(
                        ","
                      ) +
                      "));",
                    r = new Blob([e], { type: "text/javascript" }),
                    a = new Worker(URL.createObjectURL(r), {
                      name: "wpTestEmojiSupports",
                    });
                  return void (a.onmessage = function (e) {
                    c((n = e.data)), a.terminate(), t(n);
                  });
                } catch (e) {}
              c((n = f(s, u, p)));
            }
            t(n);
          })
            .then(function (e) {
              for (var t in e)
                (n.supports[t] = e[t]),
                  (n.supports.everything =
                    n.supports.everything && n.supports[t]),
                  "flag" !== t &&
                    (n.supports.everythingExceptFlag =
                      n.supports.everythingExceptFlag && n.supports[t]);
              (n.supports.everythingExceptFlag =
                n.supports.everythingExceptFlag && !n.supports.flag),
                (n.DOMReady = !1),
                (n.readyCallback = function () {
                  n.DOMReady = !0;
                });
            })
            .then(function () {
              return e;
            })
            .then(function () {
              var e;
              n.supports.everything ||
                (n.readyCallback(),
                (e = n.source || {}).concatemoji
                  ? t(e.concatemoji)
                  : e.wpemoji && e.twemoji && (t(e.twemoji), t(e.wpemoji)));
            }));
      })((window, document), window._wpemojiSettings);
      /* ]]> */
    </script>
    <style id="wp-emoji-styles-inline-css" type="text/css">
      img.wp-smiley,
      img.emoji {
        display: inline !important;
        border: none !important;
        box-shadow: none !important;
        height: 1em !important;
        width: 1em !important;
        margin: 0 0.07em !important;
        vertical-align: -0.1em !important;
        background: none !important;
        padding: 0 !important;
      }
    </style>
    <style id="classic-theme-styles-inline-css" type="text/css">
      /*! This file is auto-generated */
      .wp-block-button__link {
        color: #fff;
        background-color: #32373c;
        border-radius: 9999px;
        box-shadow: none;
        text-decoration: none;
        padding: calc(0.667em + 2px) calc(1.333em + 2px);
        font-size: 1.125em;
      }
      .wp-block-file__button {
        background: #32373c;
        color: #fff;
        text-decoration: none;
      }
    </style>
    <style id="global-styles-inline-css" type="text/css">
      :root {
        --wp--preset--aspect-ratio--square: 1;
        --wp--preset--aspect-ratio--4-3: 4/3;
        --wp--preset--aspect-ratio--3-4: 3/4;
        --wp--preset--aspect-ratio--3-2: 3/2;
        --wp--preset--aspect-ratio--2-3: 2/3;
        --wp--preset--aspect-ratio--16-9: 16/9;
        --wp--preset--aspect-ratio--9-16: 9/16;
        --wp--preset--color--black: #000000;
        --wp--preset--color--cyan-bluish-gray: #abb8c3;
        --wp--preset--color--white: #ffffff;
        --wp--preset--color--pale-pink: #f78da7;
        --wp--preset--color--vivid-red: #cf2e2e;
        --wp--preset--color--luminous-vivid-orange: #ff6900;
        --wp--preset--color--luminous-vivid-amber: #fcb900;
        --wp--preset--color--light-green-cyan: #7bdcb5;
        --wp--preset--color--vivid-green-cyan: #00d084;
        --wp--preset--color--pale-cyan-blue: #8ed1fc;
        --wp--preset--color--vivid-cyan-blue: #0693e3;
        --wp--preset--color--vivid-purple: #9b51e0;
        --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(
          135deg,
          rgba(6, 147, 227, 1) 0%,
          rgb(155, 81, 224) 100%
        );
        --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(
          135deg,
          rgb(122, 220, 180) 0%,
          rgb(0, 208, 130) 100%
        );
        --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(
          135deg,
          rgba(252, 185, 0, 1) 0%,
          rgba(255, 105, 0, 1) 100%
        );
        --wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(
          135deg,
          rgba(255, 105, 0, 1) 0%,
          rgb(207, 46, 46) 100%
        );
        --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(
          135deg,
          rgb(238, 238, 238) 0%,
          rgb(169, 184, 195) 100%
        );
        --wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(
          135deg,
          rgb(74, 234, 220) 0%,
          rgb(151, 120, 209) 20%,
          rgb(207, 42, 186) 40%,
          rgb(238, 44, 130) 60%,
          rgb(251, 105, 98) 80%,
          rgb(254, 248, 76) 100%
        );
        --wp--preset--gradient--blush-light-purple: linear-gradient(
          135deg,
          rgb(255, 206, 236) 0%,
          rgb(152, 150, 240) 100%
        );
        --wp--preset--gradient--blush-bordeaux: linear-gradient(
          135deg,
          rgb(254, 205, 165) 0%,
          rgb(254, 45, 45) 50%,
          rgb(107, 0, 62) 100%
        );
        --wp--preset--gradient--luminous-dusk: linear-gradient(
          135deg,
          rgb(255, 203, 112) 0%,
          rgb(199, 81, 192) 50%,
          rgb(65, 88, 208) 100%
        );
        --wp--preset--gradient--pale-ocean: linear-gradient(
          135deg,
          rgb(255, 245, 203) 0%,
          rgb(182, 227, 212) 50%,
          rgb(51, 167, 181) 100%
        );
        --wp--preset--gradient--electric-grass: linear-gradient(
          135deg,
          rgb(202, 248, 128) 0%,
          rgb(113, 206, 126) 100%
        );
        --wp--preset--gradient--midnight: linear-gradient(
          135deg,
          rgb(2, 3, 129) 0%,
          rgb(40, 116, 252) 100%
        );
        --wp--preset--font-size--small: 13px;
        --wp--preset--font-size--medium: 20px;
        --wp--preset--font-size--large: 36px;
        --wp--preset--font-size--x-large: 42px;
        --wp--preset--spacing--20: 0.44rem;
        --wp--preset--spacing--30: 0.67rem;
        --wp--preset--spacing--40: 1rem;
        --wp--preset--spacing--50: 1.5rem;
        --wp--preset--spacing--60: 2.25rem;
        --wp--preset--spacing--70: 3.38rem;
        --wp--preset--spacing--80: 5.06rem;
        --wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);
        --wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1),
          6px 6px rgba(0, 0, 0, 1);
        --wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);
      }
      :where(.is-layout-flex) {
        gap: 0.5em;
      }
      :where(.is-layout-grid) {
        gap: 0.5em;
      }
      body .is-layout-flex {
        display: flex;
      }
      .is-layout-flex {
        flex-wrap: wrap;
        align-items: center;
      }
      .is-layout-flex > :is(*, div) {
        margin: 0;
      }
      body .is-layout-grid {
        display: grid;
      }
      .is-layout-grid > :is(*, div) {
        margin: 0;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      .has-black-color {
        color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-color {
        color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-color {
        color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-color {
        color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-color {
        color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-color {
        color: var(--wp--preset--color--luminous-vivid-orange) !important;
      }
      .has-luminous-vivid-amber-color {
        color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-color {
        color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-color {
        color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-color {
        color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-color {
        color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-color {
        color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-background-color {
        background-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-background-color {
        background-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-background-color {
        background-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-background-color {
        background-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-background-color {
        background-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-amber
        ) !important;
      }
      .has-light-green-cyan-background-color {
        background-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-background-color {
        background-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-background-color {
        background-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-background-color {
        background-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-background-color {
        background-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-border-color {
        border-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-border-color {
        border-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-border-color {
        border-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-border-color {
        border-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-border-color {
        border-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-border-color {
        border-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-border-color {
        border-color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-border-color {
        border-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-border-color {
        border-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-border-color {
        border-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-border-color {
        border-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-border-color {
        border-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-vivid-cyan-blue-to-vivid-purple-gradient-background {
        background: var(
          --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple
        ) !important;
      }
      .has-light-green-cyan-to-vivid-green-cyan-gradient-background {
        background: var(
          --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan
        ) !important;
      }
      .has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-orange-to-vivid-red-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-orange-to-vivid-red
        ) !important;
      }
      .has-very-light-gray-to-cyan-bluish-gray-gradient-background {
        background: var(
          --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray
        ) !important;
      }
      .has-cool-to-warm-spectrum-gradient-background {
        background: var(
          --wp--preset--gradient--cool-to-warm-spectrum
        ) !important;
      }
      .has-blush-light-purple-gradient-background {
        background: var(--wp--preset--gradient--blush-light-purple) !important;
      }
      .has-blush-bordeaux-gradient-background {
        background: var(--wp--preset--gradient--blush-bordeaux) !important;
      }
      .has-luminous-dusk-gradient-background {
        background: var(--wp--preset--gradient--luminous-dusk) !important;
      }
      .has-pale-ocean-gradient-background {
        background: var(--wp--preset--gradient--pale-ocean) !important;
      }
      .has-electric-grass-gradient-background {
        background: var(--wp--preset--gradient--electric-grass) !important;
      }
      .has-midnight-gradient-background {
        background: var(--wp--preset--gradient--midnight) !important;
      }
      .has-small-font-size {
        font-size: var(--wp--preset--font-size--small) !important;
      }
      .has-medium-font-size {
        font-size: var(--wp--preset--font-size--medium) !important;
      }
      .has-large-font-size {
        font-size: var(--wp--preset--font-size--large) !important;
      }
      .has-x-large-font-size {
        font-size: var(--wp--preset--font-size--x-large) !important;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :root :where(.wp-block-pullquote) {
        font-size: 1.5em;
        line-height: 1.6;
      }
    </style>
    <link
      rel="stylesheet"
      id="google-fonts-css"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:wght@300;400;700&amp;display=swap"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="slick-css-css"
      href="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="aos-css-css"
      href="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="main-styles-css"
      href="../../wp-content/themes/bridgebio/styleb503.css?ver=1734517800"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="secondary-styles-css"
      href="../../wp-content/themes/bridgebio/assets/css/secondary-cssb503.css?ver=1734517800"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="onetrust-css"
      href="../../wp-content/themes/bridgebio/assets/css/onetrustb503.css?ver=1734517800"
      type="text/css"
      media="all"
    />
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery.minf43b.js?ver=3.7.1"
      id="jquery-core-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery-migrate.min5589.js?ver=3.4.1"
      id="jquery-migrate-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/scriptsb503.js?ver=1734517800"
      id="theme-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.js?ver=6.6.2"
      id="slick-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.js?ver=6.6.2"
      id="aos-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/modalb503.js?ver=1734517800"
      id="modal-js"
    ></script>
    <link rel="https://api.w.org/" href="../../wp-json/index.html" />
    <link
      rel="alternate"
      title="JSON"
      type="application/json"
      href="../../wp-json/wp/v2/posts/5769.json"
    />
    <link
      rel="EditURI"
      type="application/rsd+xml"
      title="RSD"
      href="../../xmlrpc0db0.php?rsd"
    />
    <link rel="shortlink" href="../../indexe1aa.html?p=5769" />
    <link
      rel="alternate"
      title="oEmbed (JSON)"
      type="application/json+oembed"
      href="../../wp-json/oembed/1.0/embed3cba.json?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update%2F"
    />
    <link
      rel="alternate"
      title="oEmbed (XML)"
      type="text/xml+oembed"
      href="../../wp-json/oembed/1.0/embedb748?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-inc-reports-third-quarter-2022-financial-results-and-business-update%2F&amp;format=xml"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-32x32.png"
      sizes="32x32"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-192x192.png"
      sizes="192x192"
    />
    <link
      rel="apple-touch-icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-180x180.png"
    />
    <meta
      name="msapplication-TileImage"
      content="https://bridgebio.com/wp-content/uploads/2024/02/cropped-cropped-favicon-270x270.png"
    />
    <!-- OneTrust Cookies Consent Notice start for www.bridgebio.com -->
    <script
      src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"
      type="text/javascript"
      charset="UTF-8"
      data-domain-script="0191509e-107d-7797-bc76-f2cb533e79d3"
    ></script>
    <script type="text/javascript">
      function OptanonWrapper() {}
    </script>
    <!-- End OneTrust -->
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "../../../www.googletagmanager.com/gtm5445.html?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-T94V2KL");
    </script>
    <!-- End Google Tag Manager -->
    <!-- Marker.io Script -->
    <script>
      window.markerConfig = {
        project: "66622db13004831ec32eb666",
        source: "snippet",
      };
      !(function (e, r, a) {
        if (!e.__Marker) {
          e.__Marker = {};
          var t = [],
            n = { __cs: t };
          [
            "show",
            "hide",
            "isVisible",
            "capture",
            "cancelCapture",
            "unload",
            "reload",
            "isExtensionInstalled",
            "setReporter",
            "setCustomData",
            "on",
            "off",
          ].forEach(function (e) {
            n[e] = function () {
              var r = Array.prototype.slice.call(arguments);
              r.unshift(e), t.push(r);
            };
          }),
            (e.Marker = n);
          var s = r.createElement("script");
          (s.async = 1), (s.src = "../../../edge.marker.io/latest/shim.js");
          var i = r.getElementsByTagName("script")[0];
          i.parentNode.insertBefore(s, i);
        }
      })(window, document);
    </script>
    <!-- End Marker.io Script -->
  </head>

  <body
    class="post-template-default single single-post postid-5769 single-format-standard"
  >
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-T94V2KL"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <nav
      class="nav nav--secondary nav--dark"
      style="--navbar-bg-color: transparent; position: relative"
    >
      <div class="nav--bg-color"></div>
      <div class="nav__content-wrapper">
        <div class="nav__menu-takeover"></div>
        <div class="nav__logo-container">
          <a href="../../index.html" class="" data-ol-has-click-handler="">
            <img
              src="../../bridge logo.webp"
              class="nav__logo hide-me"
              alt="BridgeBio logo"
            />
            <img
              src="../../bridge logo.webp"
              class="nav__logo"
              alt="BridgeBio logo"
            />
          </a>
        </div>
        <ul class="nav__menu">
          <li
            id="menu-item-4126"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4126"
          >
            <a href="../../about-us/index.html">about us</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6716"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6716"
              >
                <a href="../../about-us/index.html">overview</a>
              </li>
              <li
                id="menu-item-4093"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4093"
              >
                <a href="../../people/index.html">people</a>
              </li>
              <li
                id="menu-item-5080"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5080"
              >
                <a href="../../partners/index.html">partners</a>
              </li>
              <li
                id="menu-item-4159"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4159"
              >
                <a href="../../careers/index.html">careers</a>
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6309"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-6309"
          >
            <a href="../../pipeline/index.html">science &#038; pipeline</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6302"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6302"
              >
                <a href="../../pipeline/index.html#pipeline">pipeline</a>
              </li>
              <li
                id="menu-item-6306"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6306"
              >
                <a href="../../publications/index.html">publications</a>
              </li>
              <li
                id="menu-item-6315"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6315"
              >
                <a href="../../licensing-opportunities.html"
                  >licensing opportunities</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6848"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6848"
          >
            <a href="#">products</a>
            <ul class="sub-menu">
              <li
                id="menu-item-7104"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7104"
              >
                <a
                  target="_blank"
                  rel="noopener"
                  href="https://www.attruby.com/"
                  >Attruby</a
                >
              </li>
              <li
                id="menu-item-6852"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6852"
              >
                <a target="_blank" rel="noopener" href="https://nulibry.com/"
                  >Nulibry</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-4316"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4316"
          >
            <a href="../../patients-and-families/index.html"
              >patients &#038; families</a
            >
            <ul class="sub-menu">
              <li
                id="menu-item-7043"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7043"
              >
                <a href="../../patients-and-families/alexis/index.html"
                  >Alexis’ story</a
                >
              </li>
              <li
                id="menu-item-7044"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7044"
              >
                <a href="../../patients-and-families/elliott/index.html"
                  >Elliott’s story</a
                >
              </li>
              <li
                id="menu-item-7045"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7045"
              >
                <a href="../../patients-and-families/miguel/index.html"
                  >Miguel’s story</a
                >
              </li>
              <li
                id="menu-item-7046"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7046"
              >
                <a href="../../patients-and-families/tobin/index.html"
                  >Tobin’s story</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6296"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6296"
          >
            <a href="https://investor.bridgebio.com/">for investors</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6297"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6297"
              >
                <a href="https://investor.bridgebio.com/press-releases"
                  >press releases</a
                >
              </li>
              <li
                id="menu-item-6298"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6298"
              >
                <a
                  href="https://investor.bridgebio.com/news-and-events/event-calendar"
                  >events</a
                >
              </li>
              <li
                id="menu-item-6303"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6303"
              >
                <a href="https://investor.bridgebio.com/presentations"
                  >presentations</a
                >
              </li>
              <li
                id="menu-item-6299"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6299"
              >
                <a
                  href="https://investor.bridgebio.com/financials-and-filings/sec-filings"
                  >SEC filings</a
                >
              </li>
              <li
                id="menu-item-6300"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6300"
              >
                <a href="https://investor.bridgebio.com/corporate-governance"
                  >corporate governance</a
                >
              </li>
              <li
                id="menu-item-6301"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6301"
              >
                <a
                  href="https://investor.bridgebio.com/stock-information/analyst-coverage"
                  >analyst coverage</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6295"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6295"
          >
            <a href="../index.html">news</a>
          </li>
        </ul>
        <button class="nav__toggle-button" data-ol-has-click-handler="">
          <div id="hamburger"><span></span><span></span><span></span></div>
          <div id="cross"><span></span><span></span></div>
        </button>
      </div>
    </nav>
    <main class="news-detail">
      <div class="flex-row">
        <div class="flex-column two-three">
          <article class="news-detail__post-content">
            <h1 class="page__title titlecase">
              BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial
              Results and Business Update
            </h1>
            <section>
              <p style="text-align: center" align="center">
                <em
                  >&#8211; Reported positive preclinical data for its
                  next-generation KRAS</em
                ><sup><em>G12C</em></sup
                ><em
                  > GTP/GDP dual inhibitor development candidate, BBO-8520, and
                  for its novel </em
                ><em>PI3Kα:RAS breaker mechanism in late lead optimization</em>
              </p>
              <p align="center">
                <em
                  >&#8211; Reported positive updated 12-month Phase 2 data for
                  BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Enrolled Cohort 5 of Phase 2 trial of infigratinib in
                  achondroplasia, with no serious adverse events (SAEs), and no
                  adverse events that required dose modifications reported to
                  date</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Reported dosing of first lung cancer patient in Phase
                  1/2 trial of SHP2 inhibitor BBP-398 in combination with
                  Amgen’s Lumakras (sotorasib); also reported dosing of first
                  patient in Phase 1 trial of BBP-671 in Propionic Acidemia (PA)
                  and Methylmalonic Acidemia (MMA)</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Reported updated positive data from its Phase 1/2
                  trial of BBP-812, an AAV9 gene therapy candidate for the
                  treatment of Canavan disease</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Received approval of NULIBRY (fosdenopterin) as a
                  treatment for molybdenum cofactor deficiency (MoCD) Type A in
                  Israel and the European Union (EU)</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Reported operating expense for Q3 2022 at $129.5
                  million, a reduction of 26.2% from $175.4 million in Q1 2022
                  when restructuring efforts began, and a reduction of 15.9%
                  from $153.9 million in Q2 2022.</em
                >
              </p>
              <p align="center">
                &#8211; <em>Ended quarter with $558.3</em> <em
                  >million in cash, cash equivalents and marketable securities,
                  providing financial runway into 2024</em
                >
              </p>
              <p>
                <strong
                  >PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE)
                  &#8212;</strong
                >
                BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the
                Company), a commercial-stage biopharmaceutical company focused
                on genetic diseases and cancers, today reported its financial
                results for the third quarter ended September 30, 2022 and
                provided an update on the Company’s operations.
              </p>
              <p>
                “We remain committed to focused execution across our pipeline,
                and have continued to deliver exciting data for patients,
                including in our LGMD2i and KRAS programs, while at the same
                time materially reducing our operating expenses and putting the
                Company on safe footing,” said Neil Kumar, Ph.D., founder and
                CEO of BridgeBio.
              </p>
              <p>
                “The compounds that we have developed in our RAS franchise after
                years of intensive work now allow us to clinically interrogate
                the promise of direct inhibition of active KRAS, as well as the
                potential of breaking PI3Kα:RAS binding,” added Frank McCormick,
                Ph.D., Chairman of Oncology and cofounder of BridgeBio. “RAS and
                PIK3CA are the two most common oncogenes in human tumors, and we
                hope that our programs are able to serve the vast unmet need of
                the patients that they impact.”
              </p>
              <p><strong>BridgeBio’s Key Programs</strong></p>
              <p><strong>RAS cancer portfolio:</strong></p>
              <ul type="disc">
                <li>
                  BridgeBio has selected a next-generation
                  KRAS<sup>G12C</sup> dual inhibitor development candidate,
                  BBO-8520, and plans to be in the clinic in 2023.
                </li>
                <li>
                  The Company shared promising preclinical data on BBO-8520, as
                  well as its novel PI3Kα:RAS breaker program in late lead
                  optimization, at the Fourth RAS Initiative Symposium.
                </li>
                <li>
                  BBO-8520 has shown significantly greater potency in KRAS
                  models than first-generation KRAS<sup>G12C</sup> GDP-only
                  inhibitors as measured by its ability to bind and covalently
                  modify KRAS<sup>G12C</sup>, block KRAS<sup>G12C</sup> binding
                  to effector proteins such as RAF, and inhibit downstream
                  signaling.
                </li>
                <li>
                  BBO-8520 was shown to retain potency in the context of
                  receptor tyrosine kinase drive, which renders
                  KRAS<sup>G12C</sup> GDP-only inhibitors inactive and is
                  thought to be a major mechanism of non-response and resistance
                  to first-generation agents.
                </li>
                <li>
                  BBO-8520 showed strong activity in KRAS<sup>G12C</sup> in vivo
                  models including deep regressions and differentiated efficacy
                  compared to a first-generation KRAS<sup>G12C</sup> GDP-only
                  inhibitor.
                </li>
                <li>
                  BridgeBio scientists highlighted rationale and design of
                  compounds targeting PI3Kα:RAS binding, which is a novel and
                  potentially broad MoA to target PI3Kα mutant tumors, RAS
                  mutant tumors and potentially other tumors driven by RTK
                  activation of RAS signaling.
                </li>
                <li>
                  Targeting PI3Kα activity in tumors through its interaction
                  with RAS may spare glucose metabolism, potentially allowing
                  for potent target coverage without displaying the
                  dose-limiting hyperglycemia common to PI3Kα kinase inhibitors.
                </li>
                <li>
                  RAS is the most common oncogenic driver with approximately 30%
                  of all human cancers being driven by RAS mutations, including
                  large proportions of lung, colorectal and pancreatic tumors.
                  PIK3CA is the second most common oncogene in human tumors,
                  being present in more than 30% of breast and endometrial
                  carcinomas.
                </li>
              </ul>
              <p>
                <strong
                  >Low-dose infigratinib – FGFR1-3 inhibitor for achondroplasia
                  and hypochondroplasia:</strong
                >
              </p>
              <ul type="disc">
                <li>
                  Earlier this year BridgeBio shared <a
                    href="../5706-2/index.html"
                    target="_blank"
                    rel="nofollow noopener"
                    >positive interim results from available data in Cohort 4</a
                  > from a Phase 2 trial of low-dose infigratinib in patients
                  with achondroplasia, which demonstrated an increase in
                  annualized height velocity of 1.52 cm/year in children 5 years
                  of age and older.
                </li>
                <li>
                  Given infigratinib’s profile to date, and after discussions
                  with regulators, BridgeBio started dosing children in Cohort
                  5; that cohort is now enrolled with no serious adverse events
                  (SAEs), and no adverse events that required dose modifications
                  reported to date.
                </li>
                <li>
                  The Company expects to report an update on Cohort 5 AHV in the
                  first half of 2023, followed by the initiation of a pivotal
                  Phase 3 trial.
                </li>
                <li>
                  With more than 55,000 cases estimated in the United States
                  (US) and Europe, achondroplasia is the most common form of
                  genetic short stature and one of the most common genetic
                  conditions. BridgeBio also expects to evaluate development of
                  infigratinib in other FGFR-driven skeletal dysplasias, which
                  affect more than 50,000 people in the US and Europe.
                </li>
              </ul>
              <p>
                <strong>Encaleret – Calcium-sensing receptor (</strong
                ><strong><em>CaSR</em></strong
                ><strong
                  >) inhibitor for autosomal dominant hypocalcemia type 1
                  (ADH1):</strong
                >
              </p>
              <ul type="disc">
                <li>
                  BridgeBio intends to initiate a Phase 3 pivotal study of
                  encaleret in patients with ADH1 by the end of 2022 and expects
                  to release topline data by year-end 2023.
                </li>
                <li>
                  Positive data from the Company’s Phase 2b study of encaleret
                  in ADH1 were shared earlier this year in an <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/26dea3a5-ebc2-457f-953b-bc42712745d8"
                    target="_blank"
                    rel="nofollow noopener"
                    >oral presentation</a
                  > at the Endocrine Society’s 2022 ENDO Conference.
                </li>
                <li>
                  The Phase 2b study demonstrated that treatment with encaleret
                  resulted in rapid and sustained restoration of normal mineral
                  homeostasis by day 5 of therapy which sustained at 24 weeks,
                  and encaleret was well-tolerated without any reported SAEs.
                </li>
                <li>
                  If approved, encaleret could be the first therapy indicated
                  for the treatment of ADH1, a condition caused by gain of
                  function variants of the <em>CASR</em> gene estimated to be
                  carried by 12,000 individuals in the United States alone.
                </li>
              </ul>
              <p>
                <strong
                  >BBP-418 – Glycosylation substrate for limb-girdle muscular
                  dystrophy type 2i (LGMD2i):</strong
                >
              </p>
              <ul type="disc">
                <li>
                  The Company shared updated positive Phase 2 data in a <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/f1edd6f3-4cc0-4937-9a0e-c8c3b4482268"
                    target="_blank"
                    rel="nofollow noopener"
                    >presentation</a
                  > at the World Muscle Society (WMS)
                  27<sup>th</sup> International Hybrid Annual Congress
                </li>
                <li>
                  BridgeBio engaged with regulatory health bodies to align on a
                  Phase 3 trial design and intends to initiate a Phase 3
                  clinical trial in the first half of 2023
                </li>
                <li>
                  Phase 2 results indicate the potential for BBP-418 to increase
                  glycosylation of alpha-dystroglycan (αDG), which is directly
                  linked to the underlying disease mechanism, and to drive
                  consistent improvements of muscle function in patients as
                  measured by the reduction of creatine kinase, a key marker of
                  muscle breakdown
                </li>
                <li>
                  12-month data show improvements from baseline on 10-meter walk
                  test and North Star Assessment for Dysferlinopathy, which
                  BridgeBio believes suggests a potential impact on clinical
                  function and on the rate of disease progression
                </li>
                <li>
                  If proven to be successful, BBP-418 could be the first
                  approved therapy for patients with LGMD2i
                </li>
              </ul>
              <p>
                <strong
                  >Acoramidis (AG10) – Transthyretin (TTR) stabilizer for
                  transthyretin amyloid cardiomyopathy (ATTR-CM):</strong
                >
              </p>
              <ul type="disc">
                <li>
                  The Phase 3 ATTRibute-CM trial is progressing with topline
                  data from the Month 30 primary endpoint, a hierarchical
                  composite including all-cause mortality and cardiovascular
                  hospitalizations, expected in mid-2023
                </li>
                <li>
                  The Company <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/68b89b02-a5a7-443d-8e00-0f38da4d47da"
                    target="_blank"
                    rel="nofollow noopener"
                    >presented</a
                  > updated results of the Phase 2 open-label extension of
                  acoramidis in ATTR-CM, demonstrating near-complete TTR
                  stabilization and stable or improving serum NT-proBNP levels
                  at month 30
                </li>
              </ul>
              <p>
                <strong
                  >BBP-631 – AAV5 gene therapy candidate for congenital adrenal
                  hyperplasia (CAH):</strong
                >
              </p>
              <ul type="disc">
                <li>
                  The Phase 1/2 study is ongoing with an update anticipated late
                  in 2022 or early in 2023.
                </li>
                <li>
                  With more than 75,000 patients estimated in the US and EU, CAH
                  is one of the most prevalent genetic diseases potentially
                  addressable with adeno-associated virus (AAV) gene therapy
                </li>
                <li>
                  The disease is caused by deleterious mutations in the gene
                  encoding an enzyme called 21-hydroxylase, leading to a lack of
                  endogenous cortisol production
                </li>
                <li>
                  BBP-631 is designed to provide a functional copy of the
                  21-hydroxylase-encoding gene (CYP21A2) and potentially address
                  many aspects of the disease course
                </li>
                <li>
                  If successful, BridgeBio’s investigational gene therapy would
                  be the first therapy for CAH to restore the body’s hormone and
                  steroid balance by enabling people with CAH to make their own
                  cortisol and aldosterone
                </li>
              </ul>
              <p><strong>Recent Corporate Updates</strong></p>
              <ul type="disc">
                <li>
                  <strong
                    >Updated positive data for investigational AAV9 gene therapy
                    in Canavan disease: </strong
                  >Promising pharmacodynamic data from the first three
                  participants dosed in the Phase 1/2 clinical trial of BBP-812
                  for the treatment of Canavan disease. Results showed
                  unprecedented decreases in N-acetylaspartate (NAA) in the
                  brain and urine, suggesting the therapy is producing
                  functional ASPA enzyme. Affecting approximately 1,000 children
                  in the United States and European Union, Canavan disease is an
                  ultra-rare, disabling and fatal disease with no approved
                  therapy.
                </li>
                <li>
                  <strong
                    >Approvals in Israel and EU for NULIBRY
                    (fosdenopterin): </strong
                  >The European Commission (EC) granted marketing authorization
                  for NULIBRY Powder for Solution for Injection as the first
                  therapy for the treatment of patients with molybdenum cofactor
                  deficiency (MoCD) Type A in Europe, and the State of Israel
                  Ministry of Health approved NULIBRY for Injection as a
                  treatment for MoCD Type A patients in Israel. These decisions
                  are based on the efficacy and safety data collected compared
                  to data from a natural history study. NULIBRY is the first and
                  only approved therapy in either region to treat patients with
                  MoCD Type A, an ultra-rare, life-threatening genetic disorder
                  that often progresses rapidly in infants with a median overall
                  survival age of about four years. NULIBRY was BridgeBio’s
                  first FDA-approved and EC-approved therapeutic. Medison Pharma
                  acquired commercialization rights to NULIBRY in Israel in
                  December 2019. Sentynl Therapeutics, Inc. acquired global
                  rights to NULIBRY in March 2022.
                </li>
                <li>
                  <strong
                    >First patient dosed in Phase 1/2 combination trial of
                    BridgeBio’s SHP2 inhibitor BBP-398 with Amgen’s
                    LUMAKRAS: </strong
                  >First lung cancer patient was dosed in a Phase 1/2 trial of
                  BridgeBio’s SHP2 inhibitor BBP-398 in combination with Amgen’s
                  LUMAKRAS (sotorasib) in advanced solid tumors with the <em
                    >KRAS</em
                  ><sup>G12C</sup> mutation; additionally, FDA Fast Track
                  Designation was obtained for BBP-398 in combination with
                  LUMAKRAS for adult patients with previously treated, <em
                    >KRAS</em
                  ><sup>G12C</sup> mutated, metastatic non-small-cell lung
                  cancer (NSCLC). BridgeBio has a non-exclusive clinical
                  collaboration with Amgen to evaluate the combination of
                  BBP-398 with LUMAKRAS in patients with advanced solid tumors
                  with the <em>KRAS</em><sup>G12C</sup> mutation. BridgeBio is
                  party to an exclusive license agreement with Bristol Myers
                  Squibb (BMS) to develop and commercialize BBP-398 in oncology
                  worldwide, except for in mainland China and other Asian
                  markets, which are part of BridgeBio’s strategic collaboration
                  with LianBio. BridgeBio and BMS are also investigating the
                  combination of BBP-398 with OPDIVO® (nivolumab) in patients
                  with advanced solid tumors with <em>KRAS</em> mutations.
                </li>
                <li>
                  <strong
                    >First patient dosed in Phase 1 trial of BBP-671 for
                    propionic acidemia (PA) and methylmalonic acidemia
                    (MMA): </strong
                  >An initial data readout of patients with PA and MMA is
                  expected in mid-2023. BridgeBio is also in active discussions
                  with regulators and expects to launch a pivotal Phase 2/3
                  study of BBP-671 in pantothenate kinase-associated
                  neurodegeneration (PKAN) in 2024. If successful, BBP-671 has
                  potential to be a best-in-class therapy for PA, MMA, and PKAN
                  patients, as well as the first approved oral therapy for the
                  treatment of systemic complications caused by CoA
                  deficiencies. PA, MMA, and PKAN affect an estimated 7,000
                  patients in the United States and European Union collectively.
                </li>
              </ul>
              <p>
                <strong>Third Quarter 2022 Financial Results:</strong><br />
                <strong>Cash, Cash Equivalents and Marketable Securities</strong
                ><br />
                Cash, cash equivalents and marketable securities, excluding
                restricted cash, totaled $558.3 million as of September 30,
                2022, compared to $787.5 million as of December 31, 2021. The
                net decrease of $229.2 million in cash, cash equivalents and
                marketable securities, excluding restricted cash is primarily
                attributable to net cash used in operating activities of $326.3
                million. The net cash used in operating activities for the nine
                months ended September 30, 2022 was partially offset by a $90.0
                million in upfront payment received under the License,
                Development and Commercialization Agreement between the Company,
                its affiliate, Navire Pharma, Inc., and Bristol Myers Squibb
                (the “Navire-BMS License Agreement”). During the nine months
                ended September 30, 2022, the Company also received upfront
                payments of $110.0 million from the sale of its priority review
                voucher and $10.0 million upon closing of an asset purchase
                agreement between its affiliate, Origin Biosciences, Inc., and
                Sentynl Therapeutics, Inc. The Company made a $20.5 million
                mandatory prepayment of a portion of its term loan obligations
                under its Amended Loan and Security Agreement in connection with
                the upfront payment received from BMS.
              </p>
              <p>
                Cash, cash equivalents and marketable securities, excluding
                restricted cash, decreased by $130.3 million when compared to
                the balance as of June 30, 2022 of $688.6 million. Net cash used
                in operating activities, was $135.2 million for the three months
                ended September 30, 2022. Net cash used in operating activities
                was $191.1 million for the six months ended June 30, 2022.
              </p>
              <p>
                <strong>Operating Costs and Expenses</strong><br />
                Operating costs and expenses for the three and nine months ended
                September 30, 2022 were $129.5 million and $458.7 million,
                respectively, as compared to $151.8 million and $467.8 million
                for the same periods in the prior year. The overall decrease in
                operating costs and expenses for the three and nine months ended
                September 30, 2022 compared to the comparative periods was
                mainly due to overall decreases in selling, general and
                administrative expenses and research, development and other
                (R&amp;D) expenses resulting from the Company&#8217;s
                reprioritization of its R&amp;D programs and streamlining of
                costs. The effects of the Company&#8217;s restructuring
                initiative that was started in the first quarter of 2022 are now
                being realized due to reductions of its operating costs and
                expenses. Restructuring, impairment and related charges for the
                three and nine months ended September 30, 2022 of $5.0 million
                and $36.1 million, respectively, were primarily comprised of
                winding down costs, exit and other related costs, impairments
                and write-offs of long-lived assets, and severance and
                employee-related costs. The Company continues to evaluate
                restructuring alternatives to drive operational changes in
                business processes, efficiencies, and cost savings.
              </p>
              <p>
                “We continue to take action to protect the Company, shore up our
                balance sheet, and preserve capital to read out our upcoming key
                catalysts,” said Brian Stephenson, Ph.D., CFA, Chief Financial
                Officer of BridgeBio. “We expect that cash burn will continue to
                decline in the fourth quarter as a result of ongoing potential
                business development and restructuring activities. Cash on hand
                provides us with runway into 2024, and we will continue to look
                for ways to extend runway via potential royalty monetizations,
                partnerships, and burn reduction.”
              </p>
              <p>
                The Company’s research and development and other expenses have
                not been significantly impacted by the global COVID-19 pandemic
                for the periods presented. While BridgeBio experienced some
                delays in certain of its clinical enrollment and trial
                commencement activities, it continues to adapt with alternative
                site, telehealth and home visits, and at-home drug delivery, as
                well as mitigation strategies with its contract manufacturing
                organizations. The longer-term impact, if any, of COVID-19 on
                BridgeBio’s operating costs and expenses is currently unknown.
              </p>
              <p align="center">
                <strong>BRIDGEBIO PHARMA, INC.</strong><br />
                <strong>Condensed Consolidated Statements of Operations</strong
                ><br />
                <strong
                  >(in thousands, except shares and per share amounts)</strong
                >
              </p>
              <div class="extended-table-container">
                <div class="table-wrap">
                  <table align="center">
                    <tbody>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="6">
                          <strong>Three Months Ended September 30,</strong>
                        </td>
                        <td></td>
                        <td></td>
                        <td colspan="6">
                          <strong>Nine Months Ended September 30,</strong>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2022</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2021</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2022</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2021</strong></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="6"><strong>(Unaudited)</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="6"><strong>(Unaudited)</strong></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Revenue</td>
                        <td></td>
                        <td>$</td>
                        <td>338</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>2,344</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>75,778</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>56,830</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Operating costs and expenses:</td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Research, development and others</td>
                        <td></td>
                        <td></td>
                        <td>93,250</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>105,759</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>311,347</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>330,387</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Selling, general and administrative</td>
                        <td></td>
                        <td></td>
                        <td>31,188</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>46,084</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>111,327</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>137,461</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Restructuring, impairment and related charges</td>
                        <td></td>
                        <td></td>
                        <td>5,016</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>36,074</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Total operating costs and expenses</td>
                        <td></td>
                        <td></td>
                        <td>129,454</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>151,843</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>458,748</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>467,848</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Loss from operations</td>
                        <td></td>
                        <td></td>
                        <td>(129,116)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(149,499)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(382,970)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(411,018)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Other income (expense), net:</td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Interest income</td>
                        <td></td>
                        <td></td>
                        <td>2,417</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>234</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>3,450</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>951</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Interest expense</td>
                        <td></td>
                        <td></td>
                        <td>(19,825)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(11,067)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(60,448)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(31,644)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Gain from sale of priority review voucher, net</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>107,946</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Other income (expense), net</td>
                        <td></td>
                        <td></td>
                        <td>6,331</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(684)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(12,060)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>7,539</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Total other income (expense), net</td>
                        <td></td>
                        <td></td>
                        <td>(11,077)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(11,517)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>38,888</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(23,154)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Net loss</td>
                        <td></td>
                        <td></td>
                        <td>(140,193)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(161,016)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(344,082)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(434,172)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Net loss attributable to redeemable convertible
                          noncontrolling interests and noncontrolling interests
                        </td>
                        <td></td>
                        <td></td>
                        <td>2,854</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>5,081</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>490</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>18,810</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Net loss attributable to common stockholders<br />
                          of BridgeBio
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>(137,339)</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>(155,935)</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>(343,592)</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>(415,362)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Net loss per share, basic and diluted</td>
                        <td></td>
                        <td>$</td>
                        <td>(0.93)</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>(1.06)</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>(2.34)</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>(2.88)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Weighted-average shares used in computing net<br />
                          loss per share, basic and diluted
                        </td>
                        <td></td>
                        <td></td>
                        <td>147,937,817</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>146,662,756</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>146,842,453</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>144,044,360</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="6">
                          <strong>Three Months Ended September 30,</strong>
                        </td>
                        <td></td>
                        <td></td>
                        <td colspan="6">
                          <strong>Nine Months Ended September 30,</strong>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2022</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2021</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2022</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2021</strong></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="6"><strong>(Unaudited)</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="6"><strong>(Unaudited)</strong></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Research, development and others</td>
                        <td></td>
                        <td>$</td>
                        <td>6,137</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>4,808</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>29,046</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>46,541</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Selling, general and administrative</td>
                        <td></td>
                        <td></td>
                        <td>12,521</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>11,322</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>41,026</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>36,520</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Restructuring, impairment and related charges</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>1,172</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>  Total stock-based compensation</td>
                        <td></td>
                        <td>$</td>
                        <td>18,658</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>16,130</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>71,244</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>83,061</td>
                        <td></td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div>
              <p align="center">
                <strong>BRIDGEBIO PHARMA, INC.</strong><br />
                <strong>Condensed Consolidated Balance Sheets</strong><br />
                <strong>(In thousands)</strong>
              </p>
              <div class="extended-table-container">
                <div class="table-wrap">
                  <table align="center">
                    <tbody>
                      <tr>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>September 30,</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="3"><strong>December 31,</strong></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2022</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2021</strong></td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td><strong>Assets</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>(Unaudited)</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>(1)</strong></td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Cash and cash equivalents and marketable securities
                        </td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>558,315</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>787,515</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Investment in equity securities</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>33,662</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>49,148</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Receivable from licensing and collaboration agreements
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>24,581</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>19,749</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Prepaid expenses and other current assets</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>25,661</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>32,446</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Property and equipment, net</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>15,603</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>30,066</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Operating lease right-of-use assets</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>11,738</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>15,907</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Intangible assets, net</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>29,310</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>44,934</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Other assets</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>29,870</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>33,027</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>  Total assets</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>728,740</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>1,012,792</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          <strong
                            >Liabilities, Redeemable Convertible Noncontrolling
                            Interests and Stockholders’ Deficit</strong
                          >
                        </td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="3"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Accounts payable</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>10,158</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>11,884</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Accrued and other liabilities</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>104,992</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>118,247</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Operating lease liabilities</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>17,044</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>22,366</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>2029 Notes</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>734,516</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>733,119</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>2027 Notes</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>541,205</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>539,934</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Term loans</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>422,972</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>430,752</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Other long-term liabilities</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>28,226</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>22,069</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Redeemable convertible noncontrolling interests</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(2,388)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>1,423</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Total BridgeBio stockholders&#8217; deficit</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(1,138,417)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(870,414)</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Noncontrolling interests</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>10,432</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>3,412</td>
                        <td></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                            Total liabilities, redeemable convertible
                          noncontrolling interests and stockholders’ deficit
                        </td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>728,740</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>1,012,792</td>
                        <td></td>
                        <td></td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div>
              <div class="extended-table-container">
                <div class="table-wrap">
                  <table>
                    <tbody>
                      <tr>
                        <td>(1</td>
                        <td>)</td>
                        <td>
                          The condensed consolidated financial statements as of
                          and for the year ended December 31, 2021 are derived
                          from the audited consolidated financial statements as
                          of that date.
                        </td>
                      </tr>
                      <tr>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div>
              <p align="center">
                <strong>BRIDGEBIO PHARMA, INC.</strong><br />
                <strong>Condensed Consolidated Statements of Cash Flows</strong
                ><br />
                <strong>(In thousands)</strong>
              </p>
              <div class="extended-table-container">
                <div class="table-wrap">
                  <table align="center">
                    <tbody>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="6">
                          <strong>Nine Months Ended September 30,</strong>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2022</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2021</strong></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="6"><strong>(Unaudited)</strong></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td><strong>Operating activities:</strong></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Net loss</td>
                        <td></td>
                        <td>$</td>
                        <td>(344,082)</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>(434,172)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Adjustments to reconcile net loss to net cash used in
                          operating activities:
                        </td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Stock-based compensation</td>
                        <td></td>
                        <td></td>
                        <td>69,770</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>79,731</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Depreciation and amortization</td>
                        <td></td>
                        <td></td>
                        <td>5,111</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>4,317</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Net loss from investment in equity securities</td>
                        <td></td>
                        <td></td>
                        <td>12,969</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>1,510</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Gain from sale of priority review voucher, excluding
                          transaction costs
                        </td>
                        <td></td>
                        <td></td>
                        <td>(110,000)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Gain from recognition of receivable from licensing and
                          collaboration agreement
                        </td>
                        <td></td>
                        <td></td>
                        <td>(12,500)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Fair value of shares issued under a license agreement
                        </td>
                        <td></td>
                        <td></td>
                        <td>4,567</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Accretion of debt</td>
                        <td></td>
                        <td></td>
                        <td>6,469</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>4,043</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Fair value adjustment of warrants</td>
                        <td></td>
                        <td></td>
                        <td>1,446</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>459</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Loss on sale of certain assets</td>
                        <td></td>
                        <td></td>
                        <td>6,261</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Impairment of long-lived assets</td>
                        <td></td>
                        <td></td>
                        <td>12,720</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>3,300</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>LEO call option income</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(5,550)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Other noncash adjustments</td>
                        <td></td>
                        <td></td>
                        <td>4,687</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>7,322</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Changes in operating assets and liabilities:</td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Receivable from licensing and collaboration agreements
                        </td>
                        <td></td>
                        <td></td>
                        <td>(832)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(7,710)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Receivable from a related party</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(462)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Prepaid expenses and other current assets</td>
                        <td></td>
                        <td></td>
                        <td>4,072</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(3,743)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Other assets</td>
                        <td></td>
                        <td></td>
                        <td>10,095</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(8,930</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Accounts payable</td>
                        <td></td>
                        <td></td>
                        <td>(1,725)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>1,360</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Accrued compensation and benefits</td>
                        <td></td>
                        <td></td>
                        <td>(9,122)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(4,443)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Accrued research and development liabilities</td>
                        <td></td>
                        <td></td>
                        <td>452</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>4,686</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Accrued professional services</td>
                        <td></td>
                        <td></td>
                        <td>(2,556)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>346</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Operating lease liabilities</td>
                        <td></td>
                        <td></td>
                        <td>(4,819)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(4,474)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Deferred revenue</td>
                        <td></td>
                        <td></td>
                        <td>16,969</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Other accrued and other long-term liabilities</td>
                        <td></td>
                        <td></td>
                        <td>3,797</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(1,629)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Net cash used in operating activities</td>
                        <td></td>
                        <td></td>
                        <td>(326,251)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(364,039)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td><strong>Investing activities:</strong></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Purchases of marketable securities</td>
                        <td></td>
                        <td></td>
                        <td>(134,635)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(575,478)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Maturities of marketable securities</td>
                        <td></td>
                        <td></td>
                        <td>452,819</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>305,200</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Sales of marketable securities</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>98,925</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Purchases of investment in equity securities</td>
                        <td></td>
                        <td></td>
                        <td>(26,312)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(23,960)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Sales of investment in equity securities</td>
                        <td></td>
                        <td></td>
                        <td>28,830</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>4,743</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Increase in cash and cash equivalents from
                          consolidation of PellePharm
                        </td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>13,654</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Acquisition and payment of an intangible asset</td>
                        <td></td>
                        <td></td>
                        <td>(1,500)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(35,000)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Proceeds from sale of priority review voucher</td>
                        <td></td>
                        <td></td>
                        <td>110,000</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Proceeds from sale of certain assets</td>
                        <td></td>
                        <td></td>
                        <td>10,000</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Purchases of property and equipment</td>
                        <td></td>
                        <td></td>
                        <td>(4,020)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(10,710)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Net cash provided by (used in) investing activities
                        </td>
                        <td></td>
                        <td></td>
                        <td>435,182</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(222,626)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td><strong>Financing activities:</strong></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Proceeds from issuance of 2029 Notes</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>747,500</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Issuance costs and discounts associated with issuance
                          of 2029 Notes
                        </td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(16,064)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Issuance costs associated with term loan</td>
                        <td></td>
                        <td></td>
                        <td>(1,120)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Purchase of capped calls</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(61,295)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Repurchases of common stock</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(198,458)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Transactions with noncontrolling interests</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>3,500</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Repurchase of Eidos noncontrolling interest, including
                          direct transaction costs
                        </td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(85,090)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Proceeds from term loan</td>
                        <td></td>
                        <td></td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>25,000</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Repayment of term loan</td>
                        <td></td>
                        <td></td>
                        <td>(20,486)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(18,108)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Proceeds from BridgeBio common stock issuances under
                          ESPP
                        </td>
                        <td></td>
                        <td></td>
                        <td>2,558</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>3,821</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Repurchase of shares to satisfy tax withholding</td>
                        <td></td>
                        <td></td>
                        <td>(1,072)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(4,035)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Proceeds from stock option exercises, net of
                          repurchases
                        </td>
                        <td></td>
                        <td></td>
                        <td>609</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>14,294</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Net cash provided by (used in) financing activities
                        </td>
                        <td></td>
                        <td></td>
                        <td>(19,511)</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>411,065</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Net increase in cash, cash equivalents and restricted
                          cash
                        </td>
                        <td></td>
                        <td></td>
                        <td>89,420</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>(175,600)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Cash, cash equivalents and restricted cash at
                          beginning of period
                        </td>
                        <td></td>
                        <td></td>
                        <td>396,365</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>358,679</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Cash, cash equivalents and restricted cash at end of
                          period
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>485,785</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>183,079</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="6">
                          <strong>Nine Months Ended September 30,</strong>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2022</strong></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"><strong>2021</strong></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          <strong
                            >Supplemental Disclosures of Cash Flow
                            Information:</strong
                          >
                        </td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Cash paid for interest</td>
                        <td></td>
                        <td>$</td>
                        <td>47,575</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>28,239</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          <strong
                            >Supplemental Disclosures of Noncash Investing and
                            Financing Information:</strong
                          >
                        </td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Payment-in-kind interest added to principal of term
                          loan
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>8,503</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>—</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Net noncash portion of repurchase of Eidos
                          noncontrolling interests
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>38,167</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Direct transaction costs in the repurchase of Eidos
                          recorded in “Additional paid-in capital”<br />
                          previously classified in “Prepaid expenses and other
                          current assets”
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>8,749</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Noncash contribution by a noncontrolling interest
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>21,600</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Recognized intangible asset recorded in “Accrued
                          research and development liabilities”
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>11,000</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>12,500</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Leasehold improvements paid by landlord</td>
                        <td></td>
                        <td>$</td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>2,449</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Repurchase of common stock recorded in Accounts
                          payable
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>—</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>1,542</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Transfers from noncontrolling interests</td>
                        <td></td>
                        <td>$</td>
                        <td>1,153</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>(221)</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          <strong
                            >Reconciliation of Cash, Cash Equivalents and
                            Restricted Cash:</strong
                          >
                        </td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                        <td></td>
                        <td colspan="2"></td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Cash and cash equivalents</td>
                        <td></td>
                        <td>$</td>
                        <td>483,235</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>180,347</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Restricted cash — Included in “Prepaid expenses and
                          other current assets”
                        </td>
                        <td></td>
                        <td></td>
                        <td>140</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>176</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>Restricted cash — Included in “Other assets”</td>
                        <td></td>
                        <td></td>
                        <td>2,410</td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td>2,556</td>
                        <td></td>
                      </tr>
                      <tr>
                        <td>
                          Total cash, cash equivalents and restricted cash at
                          end of period shown in the<br />
                          condensed consolidated statements of cash flows
                        </td>
                        <td></td>
                        <td>$</td>
                        <td>485,785</td>
                        <td></td>
                        <td></td>
                        <td>$</td>
                        <td>183,079</td>
                        <td></td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div>
              <p>
                <strong>About BridgeBio Pharma, Inc.</strong><br />
                BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage
                biopharmaceutical company founded to discover, create, test and
                deliver transformative medicines to treat patients who suffer
                from genetic diseases and cancers with clear genetic drivers.
                BridgeBio’s pipeline of development programs ranges from early
                science to advanced clinical trials. BridgeBio was founded in
                2015 and its team of experienced drug discoverers, developers
                and innovators are committed to applying advances in genetic
                medicine to help patients as quickly as possible. For more
                information visit <a
                  href="../../index.html"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong>bridgebiodev.wpengine.com</strong></a
                > and follow us on <a
                  href="https://www.linkedin.com/company/bridgebio/"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong>LinkedIn</strong></a
                > and <a
                  href="https://twitter.com/BridgeBioPharma"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong>Twitter</strong></a
                >.
              </p>
              <p>
                <strong
                  >BridgeBio Pharma, Inc. Forward-Looking Statements</strong
                >
              </p>
              <p>
                This press release contains forward-looking statements.
                Statements in this press release may include statements that are
                not historical facts and are considered forward-looking within
                the meaning of Section 27A of the Securities Act of 1933, as
                amended (the Securities Act), and Section 21E of the Securities
                Exchange Act of 1934, as amended (the Exchange Act), which are
                usually identified by the use of words such as “anticipates,”
                “believes,” “estimates,” “expects,” “intends,” “may,” “plans,”
                “projects,” “seeks,” “should,” “will,” and variations of such
                words or similar expressions. We intend these forward-looking
                statements to be covered by the safe harbor provisions for
                forward-looking statements contained in Section 27A of the
                Securities Act and Section 21E of the Exchange Act. These
                forward-looking statements, including statements relating to the
                clinical and therapeutic potential of our programs and product
                candidates, including the timing and success of our RAS program,
                including preclinical data for our next-generation KRASG12C
                GTP/GDP dual inhibitor development candidate, BBO-8520 and plans
                to be in the clinic in mid-2023, updated data from our Phase 2
                study of BBP-418 for patients LGMD2i, the timing and success of
                regulatory discussions regarding potential paths to approval for
                BBP-418, the ability of BBP-418 to be the first approved therapy
                for patients with LGMD2i, the timing and success of a Phase 3
                trial of BBP-418 in patients with LGMD2i intended to be
                initiated in the first half of 2023, the availability and
                success of data from our ongoing Phase 1/2 trial of SHP2
                inhibitor BBP-398 in combination with Amgen’s Lumakras
                (sotorasib), the availability and success of additional data
                from our ongoing Phase 1/2 trial of BBP-812 for the treatment of
                Canavan disease, the availability and success of additional data
                from our ongoing Phase 1 study of BBP-671 for PKAN and organic
                acidemias, the approval of NULIBRY (fosdenopterin) for treatment
                of MoCD Type A in Israel and the EU, the availability and
                success of initial data from our ongoing Phase 2 study
                of low-dose infigratinib for achondroplasia, including plans to
                deliver an update on Cohort 5 in the first half of 2023,
                followed by the initiation of a pivotal Phase 3 trial, the
                evaluation of the development of infigratinib in other
                FGFR-driven skeletal dysplasias, the availability and success of
                additional data from our ongoing Phase 2b study of encaleret for
                ADH1, the timing and success of additional trials of encaleret
                for ADH1, including the timing and announced design of a Phase 3
                pivotal study of encaleret for ADH1, the timing and success of
                our planned Phase 3 pivotal study of encaleret in patients with
                ADH1, the availability and success of topline results from the
                Part B Month 30 endpoint of our Phase 3 ATTRibute-CM trial of
                acoramidis, expected in mid-2023, the availability and success
                of data from our ongoing Phase 1/2 study of BBP-631 for CAH,
                with an update anticipated in late 2023 or early 2023, the
                timing, availability and success of an initial data readout from
                our Phase 1 trial of BBP-671 in patients with PA and MMA
                expected in mid-2023, the timing and success of discussions with
                regulators and the expected launch of a pivotal Phase 2/3 study
                of BBP-671 in PKAN in 2024, the potential of BBP-671 to be a
                best-in-class therapy for PA, MMA, and PKAN patients, as well
                as the first approved oral therapy for the treatment of systemic
                complications caused by CoA deficiencies, if successful, the
                success of our license agreement with Bristol Myers Squibb to
                develop and commercialize BBP-398, including our eligibility for
                development, regulatory and sales milestone payments and tiered
                royalties, the success of our asset purchase agreement with
                Sentynl Therapeutics, including our ability to achieve future
                milestone and royalty payments from Sentynl Therapeutics and the
                timing of these events, the timing and success of partnering and
                out-licensing discussions for certain programs in our pipeline,
                the timing and availability of delayed debt draws under our
                senior secured credit facility, the success of our reduction in
                operating expenses and our expectations for our operating
                expenses and cash burn for the second quarter, the success of
                our restructuring initiative and its savings being realized, as
                well as our anticipated cash runway, reflect our current views
                about our plans, intentions, expectations and strategies, which
                are based on the information currently available to us and on
                assumptions we have made. Although we believe that our plans,
                intentions, expectations and strategies as reflected in or
                suggested by those forward-looking statements are reasonable, we
                can give no assurance that the plans, intentions, expectations
                or strategies will be attained or achieved. Furthermore, actual
                results may differ materially from those described in the
                forward-looking statements and will be affected by a number of
                risks, uncertainties and assumptions, including, but not limited
                to, initial and ongoing data from our preclinical studies and
                clinical trials not being indicative of final data, the
                potential size of the target patient populations our product
                candidates are designed to treat not being as large as
                anticipated, the design and success of ongoing and planned
                clinical trials, future regulatory filings, approvals and/or
                sales, despite having ongoing and future interactions with the
                FDA or other regulatory agencies to discuss potential paths to
                registration for our product candidates, the FDA or such other
                regulatory agencies not agreeing with our regulatory approval
                strategies, components of our filings, such as clinical trial
                designs, conduct and methodologies, or the sufficiency of data
                submitted, the continuing success of our collaborations, the
                Company’s ability to unlock additional funding under our credit
                facility, potential volatility in our share price, potential
                adverse impacts due to the global COVID-19 pandemic such as
                delays in regulatory review, manufacturing and supply chain
                interruptions, adverse effects on healthcare systems and
                disruption of the global economy, as well as those risks set
                forth in the Risk Factors section of our Annual Report on
                Form 10-K for the year ended December 31, 2021 and our other
                filings with the U.S. Securities and Exchange Commission.
                Moreover, we operate in a very competitive and rapidly changing
                environment in which new risks emerge from time to time. These
                forward-looking statements are based upon the current
                expectations and beliefs of our management as of the date of
                this press release, and are subject to certain risks and
                uncertainties that could cause actual results to differ
                materially from those described in the forward-looking
                statements. Except as required by applicable law, we assume no
                obligation to update publicly any forward-looking statements,
                whether as a result of new information, future events or
                otherwise.
              </p>
              <p>
                <strong>BridgeBio Contact:</strong><br />
                Vikram Bali<br />
                <strong
                  ><a
                    href="../../cdn-cgi/l/email-protection.html"
                    class="__cf_email__"
                    data-cfemail="5d3e3233293c3e291d3f2f34393a383f343239382b732a2d38333a343338733e3230"
                    >[email&#160;protected]</a
                  ></strong
                ><br />
                (650)-789-8220
              </p>
            </section>
          </article>
        </div>
        <div class="flex-column one-three listing no-cap">
          <header class="intro">
            <h4><a href="../index.html" class="red uppercase">News</a></h4>
            <small class="date">11.03.2022</small>
            <hr />
            <p>
              <em>Hope through rigorous science</em> - medicines with
              transformative potential for patients with unmet needs.
            </p>
            <p>
              <a href="../../about-us/index.html" class="button">Our Mission</a>
            </p>
          </header>
        </div>
      </div>
    </main>

    <footer class="footer">
      <div class="content-form text-center">
        <h2>join our mailing list</h2>
        <p class="stay-informed">
          Stay informed on everything that is happening at BridgeBio.
        </p>
        <button
          type="button"
          class="button sign-up-button button--secondary-blue"
        >
          <span>SIGN UP</span>
          <img
            src="../../wp-content/themes/bridgebio/assets/img/icons/chevron-down-light.svg"
            width="24px"
            alt=""
          />
        </button>
        <div class="content-form">
          <p class="thank-you-message">Thanks for submitting the form.</p>
          <script
            data-cfasync="false"
            src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
          ></script>
          <script src="../../../pages.bridgebio.com/js/forms2/js/forms2.min.js"></script>
          <form id="mktoForm_8"></form>
          <script>
            MktoForms2.loadForm(
              "//pages.bridgebio.com",
              "848-KYN-928",
              8,
              function (form) {
                MktoForms2.whenRendered(function (form) {
                  console.log(form);
                  let formElement = form.getFormElem()[0];
                  let resizeTimeout;

                  function onResize() {
                    // Clear the previous timeout if it exists
                    if (resizeTimeout) {
                      clearTimeout(resizeTimeout);
                    }
                    // Set a new timeout to delay the execution
                    resizeTimeout = setTimeout(() => {
                      Array.from(formElement.querySelectorAll("[style]"))
                        .concat(formElement)
                        .forEach((element) => {
                          element.removeAttribute("style");
                        });
                    }, 100); // Delay of 100 milliseconds
                  }
                  // Add the event listener for the resize event
                  window.addEventListener("resize", onResize);
                  // Initial call to set content based on initial size
                  onResize();
                });
                MktoForms2.whenReady(function (form) {
                  form.onSuccess(function (values, followUpUrl) {
                    // Custom onFormSubmitted code
                    let pageCenter = document.querySelector(".content-form");

                    pageCenter.classList.add("form-thank-you");

                    if (pageCenter) {
                      pageCenter.scrollIntoView({
                        behavior: "smooth",
                        block: "center",
                      });
                    }
                    return false;
                  });
                });
              }
            );
          </script>
        </div>
      </div>

      <div class="footer-bottom-container">
        <div class="footer-top">
          <p class="form-container__phrase">
            Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest
            news.
          </p>
          <a
            href="https://www.linkedin.com/company/bridgebio"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="linkedin">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM19.5392 15.9149C21.6017 15.9149 21.6018 17.8688 21.6018 19.2953V25.5094H25.5626V18.4979C25.5626 16.464 25.2943 15.1309 24.6918 14.1743C23.9502 12.997 22.6808 12.4246 20.8124 12.4246C20.0597 12.3996 19.3141 12.5779 18.6542 12.9409C17.9943 13.3038 17.4444 13.8378 17.0624 14.4868H17.0067V12.7487H13.205V25.5128H17.165V19.192C17.1666 17.573 17.4451 15.9149 19.5392 15.9149ZM6.74992 12.7487V25.5128H10.7152V12.7487H6.74992ZM8.7299 6.39373C8.27257 6.39159 7.82483 6.52538 7.44369 6.77811C7.06255 7.03084 6.76516 7.39111 6.5892 7.81318C6.41323 8.23525 6.36698 8.70008 6.45573 9.14866C6.54449 9.59724 6.76421 10.0093 7.08765 10.3326C7.4111 10.6559 7.82347 10.8758 8.27214 10.9644C8.72081 11.053 9.18593 11.0062 9.608 10.8301C10.0301 10.654 10.3901 10.3565 10.6427 9.97534C10.8954 9.59416 11.0292 9.14652 11.0269 8.68925C11.0266 8.08079 10.785 7.49725 10.3551 7.06661C9.92515 6.63597 9.3417 6.39339 8.73316 6.39207L8.7299 6.39373Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://twitter.com/BridgeBioPharma"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="x">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM14.8257 17.9363L19.3683 24.5462H24.3333L17.5833 14.7276L23.7869 7.51691H22.3167L16.931 13.7769L12.6268 7.51691H7.66667L14.1742 16.9848L7.66667 24.5462H9.13681L14.8257 17.9363ZM22.3208 23.4914H20.0625L15.5715 17.0689L14.9132 16.1257L9.6674 8.62676H11.9257L16.1591 14.6801L16.8175 15.6233L22.3176 23.493L22.3208 23.4914Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.facebook.com/profile.php?id=61561087329761"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="facebook">
                <path
                  id="Vector"
                  d="M22.095 29.3534C19.4 29.3534 15.9527 29.3468 12.9369 29.3401H11.1282C8.93901 29.3351 7.04516 29.3309 6.13265 29.3309C5.59766 29.3309 5.52602 29.3309 5.52352 29.3309C4.76602 29.3301 4.03964 29.0287 3.50407 28.4931C2.96851 27.9574 2.66733 27.2312 2.66667 26.4738V5.52335C2.66733 4.76595 2.96851 4.03975 3.50407 3.50411C4.03964 2.96846 4.76602 2.66714 5.52352 2.66626H26.4757C27.2333 2.66692 27.9598 2.96816 28.4955 3.50383C29.0313 4.03949 29.3327 4.76581 29.3333 5.52335V26.473C29.3327 27.2305 29.0313 27.9569 28.4955 28.4925C27.9598 29.0282 27.2333 29.3294 26.4757 29.3301C26.4165 29.3459 24.9808 29.3534 22.095 29.3534ZM10.4283 13.9105V17.6775H13.7376V26.7838H17.8115V17.6784H20.8482L21.4268 13.9114H17.8123V11.4667C17.7896 10.9593 17.9512 10.4608 18.2669 10.0628C18.4813 9.84172 18.7417 9.67061 19.0298 9.5616C19.3178 9.45258 19.6264 9.40833 19.9335 9.43199H21.5766V6.22409C20.6118 6.06851 19.637 5.98358 18.6599 5.96997C18.0062 5.93934 17.353 6.03949 16.7385 6.26455C16.1241 6.48961 15.5608 6.83505 15.0816 7.28062C14.6195 7.78711 14.2627 8.38034 14.0318 9.02586C13.8009 9.67138 13.7008 10.3563 13.7368 11.0409V13.9147L10.4283 13.9105Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.youtube.com/@BridgeBioPharma-u2b"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="youtube">
                <g id="Subtract">
                  <path
                    d="M19.4085 15.3332L13.8662 12.1908V18.4755L19.4085 15.3332Z"
                    fill="black"
                  />
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M5.33317 2.6665C3.86041 2.6665 2.6665 3.86041 2.6665 5.33317V26.6665C2.6665 28.1393 3.86041 29.3332 5.33317 29.3332H26.6665C28.1393 29.3332 29.3332 28.1393 29.3332 26.6665V5.33317C29.3332 3.86041 28.1393 2.6665 26.6665 2.6665H5.33317ZM24.3361 8.43791C25.2546 8.67936 25.9763 9.3882 26.2222 10.2902H26.2204C26.6665 11.9235 26.6665 15.3332 26.6665 15.3332C26.6665 15.3332 26.6665 18.7429 26.2204 20.3761C25.9746 21.2781 25.2528 21.987 24.3344 22.2284C22.6713 22.6665 15.9998 22.6665 15.9998 22.6665C15.9998 22.6665 9.32834 22.6665 7.6653 22.2284C6.74685 21.987 6.02508 21.2781 5.77922 20.3761C5.33317 18.7429 5.33317 15.3332 5.33317 15.3332C5.33317 15.3332 5.33317 11.9235 5.77922 10.2902C6.02508 9.3882 6.74685 8.67936 7.6653 8.43791C9.32834 7.99984 15.9998 7.99984 15.9998 7.99984C15.9998 7.99984 22.6713 7.99984 24.3361 8.43791Z"
                    fill="black"
                  />
                </g>
              </g>
            </svg>
          </a>
        </div>

        <div class="footer__contact">
          <p class="bold">
            &copy; 2024 BridgeBio Inc. All rights reserved. |
            <a href="https://investor.bridgebio.com/" target="_blank"
              >For Investors</a
            >
            | <a href="../../careers/index.html">careers</a> |
            <a href="../../terms-of-use/index.html">terms of use</a> |
            <a href="../../bridgebio-global-privacy-policy/index.html"
              >privacy policy</a
            >
            |
            <a href="../../cookies-notice/index.html">cookies&nbsp;notice</a> |
            <a href="../../us-expanded-access-policy/index.html"
              >us&nbsp;expanded&nbsp;access&nbsp;policy</a
            >
            | <a href="../../contact-us/index.html">contact us</a> |
            <a href="../../sms-policy/index.html">sms&nbsp;policy</a> |
            <a href="../../social-policy.html">social policy</a>
          </p>
          <p>
            3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 |
            <a
              href="../../cdn-cgi/l/email-protection.html#066f6860694664746f626163646f692865696b"
              ><span
                class="__cf_email__"
                data-cfemail="c8a1a6aea788aabaa1acafadaaa1a7e6aba7a5"
                >[email&#160;protected]</span
              ></a
            >
            | MAT-AS—0001
          </p>
        </div>
      </div>
    </footer>

    <script
      data-cfasync="false"
      src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
    ></script>
  </body>
</html>
